Plus Therapeutics (NASDAQ:PSTV) Price Target Lowered to $2.00 at Maxim Group

Plus Therapeutics (NASDAQ:PSTVGet Rating) had its price target dropped by investment analysts at Maxim Group to $2.00 in a research report issued on Thursday, Stock Target Advisor reports. Maxim Group’s price objective would suggest a potential upside of 239.04% from the stock’s previous close.

A number of other research firms have also commented on PSTV. Zacks Investment Research lowered Plus Therapeutics from a “buy” rating to a “sell” rating in a research note on Thursday, April 28th. HC Wainwright reissued a “buy” rating and issued a $7.00 price objective on shares of Plus Therapeutics in a research note on Friday, April 22nd.

PSTV stock traded up $0.06 during trading on Thursday, hitting $0.59. The company had a trading volume of 666 shares, compared to its average volume of 2,130,371. The company has a fifty day moving average price of $0.78 and a two-hundred day moving average price of $1.03. The company has a current ratio of 4.49, a quick ratio of 4.49 and a debt-to-equity ratio of 0.32. The company has a market cap of $13.09 million, a P/E ratio of -0.60 and a beta of 0.41. Plus Therapeutics has a fifty-two week low of $0.41 and a fifty-two week high of $2.95.

Plus Therapeutics (NASDAQ:PSTVGet Rating) last announced its quarterly earnings results on Thursday, February 24th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.04). On average, analysts expect that Plus Therapeutics will post -0.76 earnings per share for the current year.

Several hedge funds have recently added to or reduced their stakes in PSTV. Susquehanna International Group LLP bought a new stake in Plus Therapeutics in the fourth quarter valued at about $35,000. Citadel Advisors LLC acquired a new position in Plus Therapeutics in the second quarter valued at about $111,000. Otter Creek Advisors LLC acquired a new position in Plus Therapeutics in the first quarter valued at about $84,000. Renaissance Technologies LLC acquired a new position in Plus Therapeutics in the fourth quarter valued at about $217,000. Finally, Geode Capital Management LLC grew its stake in Plus Therapeutics by 97.6% in the third quarter. Geode Capital Management LLC now owns 258,437 shares of the company’s stock valued at $493,000 after acquiring an additional 127,644 shares during the period. Institutional investors own 8.69% of the company’s stock.

About Plus Therapeutics (Get Rating)

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.

Featured Stories

Stock Target Advisor logo

Receive News & Ratings for Plus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Plus Therapeutics and related companies with's FREE daily email newsletter.